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Maraviroc (Pfizer’s UK-427857, Selzentry or Celsentri outside the US) is the first agent in the new class
of oral HIV-1 entry inhibitors to acquire FDA and EMEA approval. It is expected that this drug will be
effective only in a subpopulation of HIV-1-infected people, namely those harbouring only the R5 virus.
The wide use of this drug is currently hampered by the lack of a readily available R5 virus only determi-
nation test (tropism test) and by insufficient scientific insight into the dynamics of R5 and X4 viruses
during infection. We discuss the challenges associated with the currently available assay, as well as
the potential role of alternative assays.
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Introduction
The chemokine receptor antagonist maraviroc is designed to
prevent HIV-1 infection by blocking the CCR5 co-receptor.
Entry of HIV-1 into a target cell requires interaction between
the envelope glycoproteins (gp120) on the surface of the virus
and the CD4 receptor and a chemokine co-receptor on the
human cell. The two main co-receptors involved in HIV entry
are CCR5 and CXCR4. Viruses that have an affinity for the
CCR5 co-receptor are called CCR5-tropic or R5, whereas those
that bind CXCR4 are known as CXCR4-tropic or X4. A dual
tropic (R5/X4) virus can bind both CCR5 and CXCR4. CCR5
antagonists are expected to be of most use in individuals
carrying R5 viruses only. For maraviroc, this hypothesis was
supported by the results of the MOTIVATE clinical trials:
MOTIVATE 1, conducted in the USA and Canada, and
MOTIVATE 2, conducted in Europe, Australia and the USA.
MOTIVATE trials
MOTIVATE 1 and 2 were randomized, double-blind studies
evaluating potency, safety and efficacy of the addition of
maraviroc to an optimized background therapy (OBT) in
antiretroviral-therapy-experienced patients with multiple class
resistance. The addition of maraviroc twice daily resulted in a
statistically significant greater viral load reduction and a signifi-
cantly greater increase in CD4þ white blood cells compared
with OBT alone. Nearly twice as many patients treated with
maraviroc plus OBT achieved undetectable viral loads
(,50 copies/mL) compared with placebo plus OBT
(MOTIVATE 1, 48.5% versus 24.6%; MOTIVATE 2, 40.8%
versus 20.9%).1,2 Based on the results of the MOTIVATE trials,
the FDA and the EMEA recently approved the use of maraviroc
for combination antiretroviral treatment of adults with evidence
of viral replication and genotypic resistance to multiple antire-
troviral agents and with only CCR5 ‘tropic HIV-1 detectable’.
Challenges associated with tropism diagnostic
requirements and maraviroc use
The restriction of maraviroc use to patients with only the
CCR5-tropic virus makes determination of the co-receptor
tropism a requisite for maraviroc initiation. A recombinant
HIV-1 co-receptor tropism assay, TrofileTM (Monogram
Biosciences, San Francisco, CA, USA), is currently the only
tropism assay that has been clinically validated for determination
of co-receptor use. The assay was used in all maraviroc clinical
development programmes with over 5000 patients being
screened. The two companies, Monogram and Pfizer, have a
collaboration agreement to make TrofileTM available for patients
on a global basis.
Practical as well as economic challenges are associated
with the dependence on TrofileTM for the use of maraviroc.
Centralized laboratory testing requires the shipment of fresh
blood or plasma specimens from all over the world to one
location in California, USA, currently the only location where
an assay of this complexity can be conducted. The assay itself is
expensive and it is currently unclear who will, in the long term,
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pay these additional costs. Besides cost, there are other issues
such as the turnaround time of 3–6 weeks and the fact that a
minimal viral load of 1000 RNA copies/mL is required for
adequate sensitivity (94% to 95% amplification success rate).3
Interpretational challenges associated with the
relation between tropism and maraviroc efficiency
Using sensitive clonal methods, Lewis et al.4 and Westby et al.5
were able to show that strains with the same genetic character-
istics as the CXCR4-using viruses isolated at maraviroc failure
were already present in small quantities in the baseline samples
of these patients but remained undetected by TrofileTM. The
limited sensitivity for the detection of minority species is an
intrinsic shortcoming of all phenotypic assays (not only Trofile).
Each ‘R5 only’ result therefore should be interpreted with
caution and is not a foregone guarantee for prolonged maraviroc
susceptibility. The FDA label for maraviroc clearly marks that
failure might be a consequence of the presence of undetected
minorities at baseline.
Mayer et al.6 evaluated the effect of maraviroc in patients
with a dual or mixed tropic virus. Although the addition of mar-
aviroc did not result in improved viral suppression compared
with OBT alone, patients in the maraviroc group experienced a
greater increase in CD4þ T cells than patients in the placebo
group (week 24: maraviroc once daily þ60, twice daily
þ62 cells, placebo þ35 cells/mm3). The effect of maraviroc in
dual or mixed tropic populations definitely needs further evalu-
ation. In particular, the influence of maraviroc on the quantitat-
ive distribution of viruses with a different tropism must be
looked at in more detail. It might be that, although not ben-
eficial, addition of maraviroc to a dual or mixed tropic virus
population is at least harmless. A study presented recently at the
Fifteenth Conference on Retroviruses and Opportunistic
Infections described a detailed analysis of the tropism of viruses
isolated from patients with virological failure in the MOTIVATE
1 and 2 trials.7 Clonal genotypic analysis allowed the classifi-
cation of viral strains that were scored as dual tropic by
TrofileTM, as dual-R or dual-X tropic, based on a comparison of
the V3 sequence with known R5 or X4 strains. It appeared that
dual-R clones may remain responsive to maraviroc, although
in vivo they always co-existed with dual-X clones. The clinical
relevance of these findings requires further investigation.
Alternative assays
Although currently the only assay with clinical validation
available, TrofileTM cannot be considered the ‘gold standard’
for tropism determination.8 Alternative technologies can be
subdivided into two groups: phenotypic and genotypic assays,
the latter linked to bioinformatics-driven prediction tools.
Phenotypic technologies are always based on the generation of
recombinant or pseudo-viruses, starting from a patient’s virus-
derived envelope. Such viruses are then used to infect cells
presenting the appropriate co-receptor. Tropism is, depending
on the assay, deduced from a luciferase, fluorescence or
b-galactosidase read-out module.9–11
The genotypic methods are based on the observation that
most of the determinants for co-receptor specificity are located
within the highly variable V3 loop of the envelope protein. A
number of bioinformatic tools have been used to develop predic-
tion algorithms, several of which are now freely available on the
Internet.12–16 A recent study by Low et al.,8 however, showed
that these genotypic algorithms are inadequate for clinical use.
Though the predictive value for X4 use of most of these algor-
ithms is high (between 88% and 97%), their use is mainly
limited by a lack of sensitivity of population-based sequencing
for the detection of minority species. The study of Low et al.
was performed on treatment-naive patients and thus not on the
patient populations studied in the MOTIVATE trials, on which
FDA and EMEA approval is currently based. Genotyping assays
may perform differently in treatment-experienced patients. In
addition, taking into account immunological markers (CD4þ) in
the genotypic algorithms might further improve their predictive
capacity.17
Are diagnostic tropism assays really feasible?
Despite the previously mentioned shortcomings, the use of geno-
typing methods for tropism prediction is tempting because it
would allow most of the routine HIV labs that are fully equipped
for the determination of genotypic drug resistance to predict
tropism in a more cost-effective and timely manner.8
In the testing cascade recently proposed (Figure 1), genotyp-
ing assays are used as first-line assays, whether in combination
with immunological markers and treatment history or not.11 If
the result of genotypic prediction algorithms indicates the
presence of X4 virus, the cascade can be stopped and the
patient considered as not eligible for maraviroc treatment. If the
results indicate an R5 or unknown tropism, additional testing,
preferably phenotypic testing, must be conducted. In a number
of clinical studies, analysis for co-receptor tropism in
treatment-experienced patients showed that the R5 virus alone
was detected in no more than half of these patients (50% to
78%) (for a recent review, see Tsibris and Kuritzkes18). The
possibility of identifying X4 virus in the remaining 32% to 50%
by genotyping would reduce the number of samples to be sent
for phenotyping by half, thereby reducing the waiting time for
advice supporting or discouraging the use of maraviroc in these
patients.
But there are a number of drawbacks and several unanswered
questions. The result of genotyping is largely dependent on the
quality of V3 loop sequencing and, due to high inter-patient
variability in the envelope gene, obtaining a good quality
sequencing result is not certain. Besides, minority species
detection in population sequencing will be at least problematic.
The quality of the prediction algorithms needs further clinical
validation and cut-offs defining clinical response to maraviroc
should be established.
After the first selection by genotyping, additional phenotypic
testing could be done using either TrofileTM or one of the
alternative assays.9–11 Although for some of these alternative
assays comparative data with Trofile are available, none has
been evaluated in clinical trials. Efforts to conduct this
evaluation must be encouraged.19 The availability of several
good quality phenotypic assays will eliminate the need for
centralization and sample transport overseas.
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The problem with minority species
Much remains unknown about the kinetics of R5 and X4 viruses
during the course of the HIV infection but increasing data
seem to support the statement that the majority of patients carry
a mixture of R5- and X4-using HIV strains.11 Using artificial
mixtures of patient-derived viral clones, phenotypic assays avail-
able today can detect minority species with a sensitivity
approaching 100% when the minority species account for 10%
of the population, dropping to 83% at 5% minority. There is
the expectation that, with new sequencing technological break-
throughs (e.g. cyclic array sequencing, ultra-deep sequencing),
this detection limit can be lowered considerably.4 With regard
to the prediction of maraviroc susceptibility, the question arises
of how deep one needs to look for minority X4 strains. Is it
the absolute number of X4 strains in the blood or the relative
amount of X4 strains in the total population that is of prognostic
value? It might be that the affinity of the virus gp120 for a
certain co-receptor presents itself not as a black and white
situation, but as a spectrum, going from R5-tropic towards
X4-tropic in a gradual scale, realized by a continued accumu-
lation of mutations in V3 and other gp120 domains. Hence,
interpretations of the impact of the X4-tropic minority species
would require relevant cut-off values for clinical response on
such a gradual scale.
Conclusions
The number of patients with limited treatment options as a result
of multidrug resistance or intolerance is continuously growing.
A promising new drug has been released to the patient’s benefit.
The clinical availability of the co-receptor antagonist maraviroc
precedes the scientific understanding that is needed to clearly
position this class of drugs in the total spectrum of treatment
options and this gap must be filled as soon as possible.
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